Drug | First author | Publication year | Age/sex | Treatment | Symptoms | Complication | Outcome | Restart of EGFR-TKI treatment | Recurrence |
---|---|---|---|---|---|---|---|---|---|
Gefitinib | Higashino (7) | 2010 | 67/F | Observation/withdrawal | Mild abdominal pain | Intra-peritoneal free air | Improved | ND | – |
Gefitinib | Iwasaku (8) | 2012 | 82/F | Observation/withdrawal | Mild abdominal pain | None | Improved | Yes | Yes |
Gefitinib | Lee (9) | 2012 | 66/F | Observation/withdrawal | Vomiting, diarrhea, and abdominal distension | Intra-hepatic portal veinous gas with suggestive of liver infarction | Improved | No | – |
Gefitinib | Wakabayashi (10) | 2012 | 83/M | Surgery/ withdrawal | Fever, vomiting, diarrhea, and severe abdominal pain | Intra-peritoneal free air, remarkable elevation of inflammatory parameters | Improved | ND | – |
Gefitinib | Otsubo (11) | 2015 | 71/M | Observation/withdrawal | Vomiting, diarrhea, and abdominal pain | Intra-peritoneal free air | Improved | Yes | No |
Gefitinib | Maeda (12) | 2016 | 80/F | Observation/withdrawal | Anorexia, constipation, and abdominal distension | Intra-peritoneal free air, mild elevation of inflammatory parameters | Improved | Yes | Yes |
Erlotinib + bevacizumab | Tsukita (13) | 2014 | 69/M | Observation/withdrawal | No symptoms | Intra-peritoneal free air | Improved | ND | – |
Erlotinib + pemetrexed | Yamamoto (14) | 2014 | 70/F | Observation, continuation of erlotinib | Vomiting, anorexia, diarrhea, and abdominal pain | None | Improved | – | – |
Erlotinib + bevacizumab | Saito (15) | 2016 | 73/F | Observation/withdrawal | Anorexia and fatigue | Intra-peritoneal free air | Improved | No | – |
Osimertinib | Current case | 2018 | 73/F | Observation/withdrawal | No symptoms | Intra-hepatic portal vein gas | Improved | Yes | No |